In a 57-year-old woman with atypical glandular cells on cervical cytology, HPV negative, and a Liletta (levonorgestrel) intrauterine device placed three years ago, what is the appropriate next diagnostic and management step?

Management of Atypical Glandular Cells in a 57-Year-Old Woman with Liletta IUD

This patient requires colposcopy with endocervical sampling AND endometrial sampling, regardless of her HPV-negative status or the presence of an IUD. The IUD effect noted on cytology does not exclude significant pathology and should not alter the standard workup for atypical glandular cells (AGC).

Immediate Diagnostic Workup Required

Based on consensus guidelines, all women with AGC require comprehensive evaluation that includes 1, 2:

• Colposcopy with endocervical sampling (mandatory for all AGC cases)
• Endometrial sampling (mandatory because she is >35 years old)
• The HPV-negative status does NOT eliminate the need for full evaluation

Why Complete Workup is Essential Despite HPV-Negative Status

While HPV testing has value in AGC management, HPV testing alone or repeat cytology alone is explicitly unacceptable as initial triage for AGC 1. Here's the critical reasoning:

• AGC can indicate significant squamous or glandular lesions in up to 38% of cases 2
• Recent data shows that even with comprehensive evaluation, 28.5% of AGC cases have adenocarcinoma in situ (AIS) or worse, 18% have CIN, and 13.3% have other malignancies 3
• HPV-negative women with AGC still have a 4% rate of HPV-associated disease and can harbor endometrial or extrauterine malignancies 4

Age-Specific Considerations

At 57 years old, this patient falls into a higher-risk category:

• Postmenopausal status (likely at age 57) is a significant risk factor for endometrial cancer in AGC patients 5
• Women ≥50 years with AGC have significantly higher rates of significant pathology 5
• In one study, 10.9% of AGC patients had invasive cervical or endometrial disease 6

The IUD Effect: Important but Not Reassuring

The cytology comment about "IUD effect" is a common finding but does not provide reassurance:

• Levonorgestrel IUDs like Liletta cause endometrial changes that can result in glandular cells appearing on cytology 7
• However, the presence of an IUD does not exclude concurrent neoplasia
• The pathologist's comment acknowledges uncertainty ("may be a result of IUD effect"), not certainty

Specific Diagnostic Protocol

Step 1: Colposcopy with Endocervical Sampling

• Perform careful colposcopic examination of the entire cervix
• Obtain endocervical curettage (ECC) or endocervical brush sampling
• Biopsy any visible lesions

Step 2: Endometrial Assessment

• Perform endometrial biopsy (office-based or via dilation and curettage)
• This is mandatory at age 57, regardless of symptoms 1
• Consider removing the Liletta IUD to facilitate adequate endometrial sampling and eliminate the confounding effect on future cytology

Step 3: Consider IUD Removal Timing

The Liletta IUD may need removal for several reasons:

• To obtain adequate endometrial sampling
• The IUD has been in place for 3 years (approved for up to 8 years for contraception) 7
• At age 57, contraceptive needs may be minimal if perimenopausal/postmenopausal
• Removing the confounding factor will clarify future surveillance

Post-Evaluation Management Based on Findings

If Initial Workup is Negative (No CIN or Glandular Neoplasia)

Since she is HPV-negative, follow-up protocol is 1:

• Repeat cytology and HPV testing at 12 months (not 6 months, since HPV-negative)
• If both remain negative, return to routine screening
• If either becomes positive, refer back to colposcopy

If High-Grade Lesions are Found

• AGC "favor neoplasia" or AIS requires diagnostic excisional procedure (LEEP or cold knife cone) with interpretable margins 1
• Any CIN 2/3 should be managed per standard CIN guidelines
• Endometrial pathology should be managed per gynecologic oncology protocols

Critical Pitfalls to Avoid

1. Do not rely on the "IUD effect" comment to defer workup - this is a potential explanation but not a diagnosis
2. Do not use HPV-negative status as reassurance - AGC requires full evaluation regardless of HPV status 1
3. Do not skip endometrial sampling - at age 57, endometrial assessment is mandatory even without bleeding 1
4. Do not perform repeat cytology as initial management - this is explicitly unacceptable for AGC 1

Risk Stratification Context

Recent evidence shows that in AGC patients 6, 5, 8:

• Overall risk of high-grade cervical or endometrial lesions: 21-28.5%
• Risk of invasive cancer: 7-14.8%
• Postmenopausal status significantly increases endometrial cancer risk
• Age ≥50 years is an independent risk factor for significant pathology

The combination of age 57, postmenopausal status (likely), and AGC cytology places this patient in a high-risk category that mandates complete evaluation before any reassurance can be provided.